Review
doi: 10.1097/PAI.0b013e31822a8eac.
ASCO-CAP guidelines for breast predictive factor testing: an update
Affiliations
- PMID: 22089488
- DOI: 10.1097/PAI.0b013e31822a8eac
Item in Clipboard
Review
ASCO-CAP guidelines for breast predictive factor testing: an update
Appl Immunohistochem Mol Morphol.
2011 Dec.
Abstract
This brief report compares and contrasts the American Society of Clinical Oncology/College of American Pathologists guidelines for breast cancer predictive factor testing including the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor, type 2, erbB2 Guideline published in 2007 and the recently published Guideline for Estrogen Receptor and Progesterone Receptor Testing by Immunohistochemistry, published in 2011.
Similar articles
-
Laboratory compliance with the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor 2 testing guidelines: a 3-year comparison of validation procedures.Arch Pathol Lab Med. 2014 Jul;138(7):876-84. doi: 10.5858/arpa.2013-0731-CP. Arch Pathol Lab Med. 2014. PMID: 24978913
-
Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome.J Clin Oncol. 2007 Dec 1;25(34):5418-25. doi: 10.1200/JCO.2007.12.8033. J Clin Oncol. 2007. PMID: 18048824
-
Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.Arch Pathol Lab Med. 2016 Feb;140(2):140-7. doi: 10.5858/arpa.2015-0108-OA. Arch Pathol Lab Med. 2016. PMID: 26910218
-
Predictive markers in breast cancer: An update on ER and HER2 testing and reporting.Semin Diagn Pathol. 2015 Sep;32(5):362-9. doi: 10.1053/j.semdp.2015.02.011. Epub 2015 Feb 7. Semin Diagn Pathol. 2015. PMID: 25770732 Review.
-
HER2 testing: current status and future directions.Cancer Treat Rev. 2014 Mar;40(2):276-84. doi: 10.1016/j.ctrv.2013.09.001. Epub 2013 Sep 11. Cancer Treat Rev. 2014. PMID: 24080154 Review.
Cited by
-
Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer.JNCI Cancer Spectr. 2021 Feb 4;5(3):pkab010. doi: 10.1093/jncics/pkab010. eCollection 2021 Jun. JNCI Cancer Spectr. 2021. PMID: 33977227 Free PMC article.
-
Immunotherapy for the Treatment of Breast Cancer: Emerging New Data.Breast Cancer (Dove Med Press). 2019 Dec 31;11:321-328. doi: 10.2147/BCTT.S184710. eCollection 2019. Breast Cancer (Dove Med Press). 2019. PMID: 32099454 Free PMC article. Review.
-
Discordance Rate in Estrogen Receptor, Progesterone Receptor, HER2 Status, and Ki67 Index Between Primary Unifocal and Multiple Homogenous Breast Carcinomas and Synchronous Axillary Lymph Node Metastases Have an Impact on Therapeutic Decision.Appl Immunohistochem Mol Morphol. 2018 Sep;26(8):533-538. doi: 10.1097/PAI.0000000000000483. Appl Immunohistochem Mol Morphol. 2018. PMID: 28099174 Free PMC article.
-
Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer.Breast Cancer Res Treat. 2021 Feb;185(3):817-830. doi: 10.1007/s10549-020-05978-8. Epub 2020 Oct 28. Breast Cancer Res Treat. 2021. PMID: 33113088 Free PMC article.
-
Triple-negative vimentin-positive heterogeneous feline mammary carcinomas as a potential comparative model for breast cancer.BMC Vet Res. 2014 Sep 25;10:185. doi: 10.1186/s12917-014-0185-8. BMC Vet Res. 2014. PMID: 25249140 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
